Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 Dec 2023
Historique:
medline: 7 12 2023
pubmed: 5 12 2023
entrez: 5 12 2023
Statut: epublish

Résumé

Trial protocols outline a trial's objectives as well as the methods (design, conduct, and analysis) that will be used to meet those objectives, and transparent reporting of trial protocols ensures objectives are clear and facilitates appraisal regarding the suitability of study methods. Factorial trials, in which 2 or more interventions are assessed in the same set of participants, have unique methodological considerations. However, no extension of the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 Statement, which provides guidance on reporting of trial protocols, for factorial trials is available. To develop a consensus-based extension to the SPIRIT 2013 Statement for factorial trials. The SPIRIT extension for factorial trials was developed using the Enhancing the Quality and Transparency of Health Research (EQUATOR) methodological framework. First, a list of reporting recommendations was generated using a scoping review of methodological articles identified using a MEDLINE search (inception to May 2019), which was supplemented with relevant articles from the personal collections of the authors. Second, a 3-round Delphi survey (January to June 2022, completed by 104 panelists from 14 countries) was conducted to assess the importance of items and identify additional recommendations. Third, a hybrid consensus meeting was held, attended by 15 panelists to finalize selection and wording of the checklist. This SPIRIT extension for factorial trials modified 9 of the 33 items in the SPIRIT 2013 checklist. Key reporting recommendations were that the rationale for using a factorial design should be provided, including whether an interaction is hypothesized; the treatment groups that will form the main comparisons should be identified; and statistical methods for each main comparison should be provided, including how interactions will be assessed. In this consensus statement, 9 factorial-specific items were provided that should be addressed in all protocols of factorial trials to increase the trial's utility and transparency.

Identifiants

pubmed: 38051535
pii: 2812568
doi: 10.1001/jamanetworkopen.2023.46121
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2346121

Auteurs

Brennan C Kahan (BC)

MRC Clinical Trials Unit at UCL, London, United Kingdom.

Sophie S Hall (SS)

Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, United Kingdom.

Elaine M Beller (EM)

Institute for Evidence-Based Healthcare, Bond University, Robina, Australia.

Megan Birchenall (M)

Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, United Kingdom.

Diana Elbourne (D)

London School of Hygiene and Tropical Medicine, London, United Kingdom.

Edmund Juszczak (E)

Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, United Kingdom.

Paul Little (P)

Primary Care Research Centre, School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.

John Fletcher (J)

The BMJ, London, United Kingdom.

Robert M Golub (RM)

Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Beatriz Goulao (B)

Health Services Research Unit, University of Aberdeen, Aberdeen, Scotland.

Sally Hopewell (S)

Oxford Clinical Trials Research Unit, University of Oxford, Oxford, United Kingdom.

Nazrul Islam (N)

Primary Care Research Centre, School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
The BMJ, London, United Kingdom.

Merrick Zwarenstein (M)

Centre For Studies in Family Medicine, Schulich School of Medicine and Dentistry, Western University, London, Canada.

An-Wen Chan (AW)

Women's College Research Institute, University of Toronto, Toronto, Canada.

Alan A Montgomery (AA)

Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH